Abstract: Antiangiogenic therapy is an essential approach in the treatment of malignant tumors along with the development of precision medicine. However, the occurrence of antiangiogenic therapy-induced hypertension, which is the most common toxicity of this agent, influences its broad clinical use (in some cases). Researches on its mechanisms, prevention, and management, have been conducted, but clinical guidelines or expert consensuses have not been reached. In this review, we presented the epidemiology, current research status, and systematic management of antiangiogenic therapy-induced hypertension.